Timothy Still Joins VolitionRx as Chairman of the Board
VolitionRx Limited (NYSE AMERICAN: VNRX), a global leader in epigenetics, has announced the appointment of Timothy Still as the new Chairman of its board of directors. His extensive experience in medical diagnostics and digital health will surely bring valuable insights to this pivotal role.
A Remarkable Career in Healthcare
Timothy Still is not new to the industry; he has over 35 years of expertise in driving innovative solutions within the medical diagnostics sector. Currently the Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner at REVIVAL Healthcare, Mr. Still's journey reflects a commitment to advancing healthcare. His previous roles included key positions at various medical technology companies, ensuring the commercialization of diagnostic products.
Recent Contributions to Diagnostics
His latest contributions came through his leadership as President and CEO of Sense Biodetection. Earlier this year, Sense Bio merged with Sherlock Biosciences, establishing itself as a significant player in the point-of-care diagnostics arena. Before that, Mr. Still held distinguished roles at Myoscience, MDx Health, Gold Standard Diagnostics, and others, showcasing his capacity to lead companies from inception to market success.
Educational Background and Vision
Academically, Timothy holds a master's degree in business administration from the University of Southern California as a Dean's Scholar, along with a Bachelor of Science degree with Highest Honors from the University of California at Davis. His educational foundation coupled with professional experience positions him well to guide Volition as it continues to innovate in diagnostic technologies.
Looking Forward to New Beginnings
On his recent appointment, Timothy expressed enthusiasm, stating, "Joining Volition at such a pivotal moment is incredibly exciting. Volition's groundbreaking epigenetic technology holds the promise of transforming global healthcare, focusing on disease detection and monitoring, ultimately improving outcomes for both people and animals on a worldwide scale."
Support from the Leadership Team
Cameron Reynolds, President and Group Chief Executive Officer of Volition, welcomed Mr. Still, highlighting his extensive experience in steering companies from research and development to commercial readiness. The board and leadership team are looking forward to leveraging his strategic insights during this crucial growth phase.
Reynolds also acknowledged the contributions of Guy Innes, who has served as the Interim Non-Executive Chair and continues to play an essential role at Volition.
Innovations in Diagnostics
VolitionRx is dedicated to developing intuitive and cost-effective blood tests, aiming to diagnose and monitor critical health conditions in humans and animals. This innovative approach strives to enhance life quality through earlier disease detection, with a focus on various healthcare challenges.
As Volition advances its research and product offerings, it positions itself to impact the diagnostics market profoundly. Plans for further innovations are underway, emphasizing accessibility and cost-efficiency.
About Volition
Volition is a multi-national organization committed to enhancing the science of epigenetics. Its mission revolves around saving lives through earlier disease detection and monitoring, leading to better patient outcomes. The company promotes the development of blood tests targeting various diseases, including certain cancers and conditions linked to NETosis, providing essential diagnostic solutions.
Research and development take place in Belgium, complemented by innovation labs in the U.S. and additional offices in London and Singapore. This global footprint underscores Volition's dedication to technological advancement in the healthcare space.
Frequently Asked Questions
Who is Timothy Still?
Timothy Still is the new Chairman of VolitionRx Limited, renowned for his extensive experience in the medical diagnostics field.
What is VolitionRx known for?
VolitionRx is recognized for advancing epigenetics and developing innovative blood tests aimed at diagnosing and monitoring health conditions.
What impact will Mr. Still have on Volition?
With his deep understanding of diagnostics, Timothy Still will guide Volition through significant growth and innovation in their product offerings.
Where is Volition's research centered?
Volition's research and development primarily occur in Belgium, with additional innovation labs in the United States.
What are the future plans for Volition?
Volition aims to continue expanding its range of tests and technologies, enhancing healthcare outcomes through earlier detection methods.
